IP Library Granted Patent US 9,533,038
Granted Patent B2
US 9,533,038 · App. 14/701,006 · Granted Jan 3, 2017

Soluble forms of hendra and nipah virus G glycoprotein

Inventors: Christopher C. Broder (Silver Spring, MD); Katharine N. Bossart (San Francisco, CA)
Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
A61K39/155C07K14/005C07K14/07C07K14/115C07K16/1027C12N7/00G01N33/56983G01N33/6854A61K39/00A61K2039/505A61K2039/6075C12N2710/24141C12N2760/18222C12N2760/18234C12N2760/18271
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,533,038
App. No.
14/701,006
Granted
Jan 3, 2017
Kind
B2
Abstract

This invention relates to soluble forms of G glycoprotein from Hendra and Nipah virus. In particular, this invention relates to compositions comprising soluble forms of G glycoprotein from Hendra and Nipah virus and also to diagnostic and therapeutic methods using the soluble forms of G glycoprotein from Hendra and Nipah virus. Further, the invention relates to therapeutic antibodies including neutralizing antibodies, and vaccines for the prevention and treatment of infection by Hendra and Nipah viruses.

Claims (7)

1. A method of preventing infection by a Hendra virus in a subject comprising administering to said subject a composition comprising an isolated oligomeric peptide wherein the monomers of the oligomeric peptide consist of the ectodomain of the Hendra virus G protein with an amino acid sequence of SEQ ID NO: 16 or a sequence at least 90% identical to SEQ ID NO: 16.

2. The method of claim 1 , wherein the isolated oligomeric peptide retains one or more characteristics of a native Hendra virus G protein.

3. The method of claim 1 , wherein the oligomeric peptide is linked to another peptide.

4. The method of claim 3 , wherein the another peptide is derived from vaccinia virus.

5. The method of claim 1 , wherein the oligomeric peptide is a dimer.

6. The method of claim 1 , wherein the oligomeric peptide is a tetramer.

7. The method of claim 1 , wherein the composition further comprises an adjuvant.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 17, 2016
From: BRODER, CHRISTOPHER
To: UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES
Reel/Frame 040361/0578 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 17, 2016
From: UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES
To: THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.
Reel/Frame 040361/0641 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 17, 2016
From: BOSSART, KATHARINE
To: THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.
Reel/Frame 040361/0742 →
CONFIRMATORY LICENSE Recorded Oct 3, 2016
From: HENRY M. JACKSON FDN FOR THE ADV MIL/MED
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 039920/0979 →
Continuity (4)
Continuation 13530922 · Jun 22, 2012
Continuation 11629682
Provisional Application 60586843 · Jul 9, 2004
Related Publication 20150306208A1 · Oct 29, 2015